One hundred patients with phlebographically proved acute deep vein thrombosis of the legs were prospectively randomised into two treatment groups to compare the safety and efficacy of subcutaneous calcium heparin versus intravenous sodium heparin admininstered by constant infusion pump.The dose of heparin was determined by daily measurement of the kaolin cephalin clotting time. Treatment was maintained for up to 14 days, after which phlebography was repeated. Of49 patients who received subcutaneous calcium heparin, two showed an increase in thrombus size, while eight showed complete lysis. In the 47 patients who received intravenous sodium heparin thrombus increased in size in 13 while only one showed evidence of complete lysis. These differences were significant. There were no significant differences between the two groups in the incidence of serious complications, although almost half ofthose receiving intravenous heparin had some minor problem with the constant infusion pump and just over half ofthose receiving subcutaneous heparin had some bruising at the injection site.
were given 250 IU/kg subcutaneously, the dose being repeated every 12 hours and adjusted to maintain the kaolin cephalin clotting time at one and a half times to twice the normal value. Daily samples for this test were obtained five to seven hours after the morning dose. To avoid bruising as much as possible calcium heparin was injected using the technique of Griffith and Boggs.
The intravenous heparin group received 250 IU/kg over 12 hours, the heparin being diluted in 50 ml of normal saline. As in the other group, the rate of infusion was adjusted to maintain the kaolin cephalin clotting time at one and a half times to twice the normal value.
Treatment was maintained for up to 14 days, oral anticoagulation being introduced three days before the end of heparin therapy. Ascending phlebography was repeated on the final day of treatment, after which the subsequent dose of warfarin sodium was controlled using the prothrombin time, which was maintained at one and a halftimes to twice the normal value.
ASSESSMENT
Phkbography-Ascending phlebography (bilateral when necessary) was carried out using non-ionic contrast medium before entry into the trial to confirm the presence of a deep vein thrombosis and to assess the extent of thrombus formation. Phlebography was repeated on the final day of treatment. Thereafterthe pretreatment and post-treatment paired phlebograms were assessed by a consultant radiologist (MLT), who had no knowledge of the patient, the treatment, or the centre from which the phlebograms had come.
Haematological-Haemoglobin concentration, packed cell volume, and platelet count were estimated on days 1, 7, and 14 during treatment. Kaolin cephalin clotting time was measured daily, five to seven hours after the morning dose.
Clinical-The patient's general condition was noted each day. In particular, the injection site was inspected twice daily, as were surgical wounds when present. Urine analysis was carried out on days 1, 7, and 14 
Results
Twenty five men, mean age 61 years (SD 11), and 25 women, mean age 63 years (16), were treated with subcutaneous calcium heparin, and 28 men, mean age 60 years (14) , and 22 women, mean age 63 years (15) , were treated with intravenous sodium heparin. The incidence ofthe various predisposing factors did not vary significantly between the two groups (table I). post-treatment phlebograms and were therefore excluded from assessment. One patient in the subcutaneous group died during the study from septicaemia secondary to a subphremic abscess; although he had completed his course of treatment, follow up phlebography was not possible. No patient was withdrawn from treatment during the study. Complications-Two patients in each group required a blood transfusion oftwo units because ofa fall in haemoglobin concentration. Otherwise, there were no major haemorrhagic complications, and the only significant difference between the two groups was bruising at the injection site in 27 of the subcutaneous group compared with only three of the intravenous group. The bruises in the subcutaneous group ranged from 7 to 17 mm in diameter, but in only two patients did they' cause severe pain. The relatively high incidence of bruising was due to a faulty injection technique which occurred in the early stages of the trial with 15 patients. Minor complications at the injection site in the intravenous group were one case of infection, one of minor allergy, and two of thrombophlebitis. The incidence of minor pulmonary embolism did not differ significantly between the two groups, occurring in two of the subcutaneous group and three of the intravenous group. Minor interruptions of treatment occurred in 21 patients in the intravenous group mostly because ofmechanical problems with the infusion pump. Dose ofheparin-The mean daily and total requirements in those receiving subcutaneous calcium heparin were both greater than in those receiving intravenous sodium heparin, although only the difference in mean daily dose was significant (p<0 02) (table IV).
Discussion
Subcutaneous injection of heparin has potential advantages over intravenous injection. Intravenous administration greatly limits the patients's mobility, and treatment may have to be interrupted if the patient needs to visit other hospital departments. Maintaining accurate dosage may also be a serious problem when mechanical problems arise with the constant infusion pump. Subcutaneous administration avoids these difficulties.
Satisfactory anticoagulant activity was shown after low dose subcutaneous administration of both calcium and sodium salts by Thomas et al,' who also found lower plasma heparin concentrations and a reduction of prolongation of the kaolin cephalin clotting time Hirsh et al found that an adequate and stable anticoagulant effect could be obtained in most patients with two daily subcutaneous injections of calcium heparin, the therapeutic level being reached within two hours and the peak value at five hours.9 Clotting time remained within the therapeutic range for about 10 hours, and complications were minor.
Although many studies have shown the benefit and safety ofsmall subcutaneous doses of heparin given as prophylaxis, few have used this method of administration to treat established acute deep vein thrombosis of the legs.' 1012 The conventional method of treating acute deep vein thrombosis remains that of administering sodium heparin intravenously for several days and supplementing this with oral anticoagulation.
Our results, comparing the conventional intravenous route with the subcutaneous route in patients with deep vein thrombosis of the legs, showed a significant difference between the two groups in the number of thrombi undergoing complete lysis and in the number increasing in size during treatment, the differences favouring subcutaneous heparin. These results concur with those ofBentley et al, who carried out a similar trial and found subcutaneous calcium heparin to be more effective in controlling extension of thrombi confined to the calf veins. 5 The mechanism for the difference in the results between the two groups remains unclear, but Bentley et al suggested three possible explanations. Firstly, patients in the calcium heparin group may have received more heparin. Although this was not the case in their study, it was in ours (table IV), although the mean total doses were not significantly different. The greater dose was reflected in a higher released. Recent work has also suggested thatheparin administration may enhance fibrinolysis by potentiating urokinase type and tissue plasminogen activators.'41s Complications in both our groups were similar, except for bruising at the injection site in those receiving subcutaneous calcium heparin. Most patients, however, were not upset by this and experienced minimal, if any, discomfort; only two complained of severe pain at the injection site. Minor interruptions oftreatment occurred in 21 patients in the intravenous group but none of the calcium heparin group. The lack ofinterruption in the subcutaneous group may have contributed to the better results obtained, as might the greater mobility afforded to the subcutaneous group. The reason for the higher dosage requirement in the calcium heparin group remains unclear, but it was not associated with any significant increase in complications.
Our results are at variance with those of Hull et al, who recently reported a randomised trial of intravenous and subcutaneously administered heparin in the treatment of established proximal vein thrombosis, in which they found a higher incidence of recurrent thromboembolism in those treated subcutaneously. 12 They failed to state, however, which salt was used in each group and whether the same batch of heparin was used throughout. Furthermore, all recurrences were in patients with an initial subtherapeutic anticoagulant response, suggesting a failure of adequate anticoagulant dosage in the subcutaneous group rather than a failure of the heparin per se. By contrast, we had no difficulty maintaining our patients within the therapeutic anticoagulant range, and patients in the subcutaneous group had, on average, higher daily kaolin cephalin clotting times than those in the intravenous group.
Our study has shown therefore that subcutaneous calcium heparin is more effective in helping lyse existing thrombus and preventing its propagation than is intravenous sodium heparin. This is true not only for minor thrombi below the knee but also for major thrombi above the knee. It is easier to administer, allows greater mobility during treatment, and is more acceptable to patients, nursing, and medical staff. On the evidence ofthis trial we feel that subcutaneous calcium heparin should be used as the first choice for managing established acute deep vein thrombosis of the legs, whether associated with pulmonary embolism or not.
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Introduction
Clinical decisions vary considerably when pregnancy continues beyond the accepted normal term.' 2 Systematic induction of labour has been justified as a means of averting placental insufficiency and fetal death. Another argument for induction is that good timing will ensure delivery during hours of optimal staffing and preparedness for emergency treatment. As some 10% ofpregnancies go beyond 42 completed weeks, even when strict criteria for reliability of menstrual dates are employed,3 a rigorous policy of induction after term generates a large extra clinical workload.
In Norway the established practice for mothers who pass the 42 week limit is to refer them to the maternity hospital for evaluation. From then on the course of action depends on local policy. In our hospital the induction policy was fairly liberal. We planned and conducted the following study in order to obtain a more rational basis for future decision making.
Patients and methods
Design ofstudy-The ideal comparison would be induction at the end of42 weeks (294 days) versus no intervention before spontaneous labour. This, however, was not feasible, as the risk of prolonged pregnancy is ultimately greater than that of any deliberate form of intervention. We decided on 303 days as the limit for non-intervention and designed a randomised study of immediate induction of labour in women referred for post-term pregnancy versus induction one week later in those who had not delivered in the interim.
Criteria for inclusion-We included in the study only healthy women with normal pregnancies. Other criteria for inclusion were a single fetus in cephalic presentation; a duration of pregnancy of 290 to 297 days from the first day of the last menstrual period; and reliable dates. Reliable dates were defined as regular menstrual periods (28±4 day intervals) and clear recollection ofdates. Use ofcontraceptive pills during the two months before the last menstrual period was a cause for exclusion. Table I lists other reasons  for exclusion. Examination, randomisation, and management-Pregnant women who had not delivered by about 42 weeks were referred by their doctors. After scrutiny of the menstrual and pregnancy histories one of us performed a clinical examination, and if all criteria for enrolment were fulfilled randomisation (non-stratified) was done. The midwife consulted a list of random numbers, which was inaccessible to the participating physicians. Women in group 1 (immediate induction) were then referred to the delivery department for induction. Those assigned to group 2 (postponement of induction) were suibmitted to cardiotocographic non-stress tests on the day of referral (day zero) and again on day 3 or 4 if still undelivered. If birth had not occurred by day 7 labour was induced. In cases of failed induction in group 1 further management was as for group 2. For mothers who were still undelivered after the attempted induction on day 7 management was left to clinical judgment.
